PTC THERAPEUTICS INC
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Director and Officer Trading Arrangements
A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other Company securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.
Transactions in Company securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in Company securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.
The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of Company securities adopted orterminated by our directors and officers that is either (1) a contract, instruction or written plan for the purchase or sale of the Company’s securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement”, or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
| Name(Title) | Action Taken(Date of Action) | Type of TradingArrangement | Nature of TradingArrangement | Duration of TradingArrangement | Aggregate Numberof Securities |
|---|---|---|---|---|---|
| Mark Boulding (Chief Legal Officer) | Adoption (December 5, 2024) | Rule 10b5-1 trading arrangement | Sale | Until March 3, 2026 or such earlier date upon which all transactions are completed. | Up to 207,636 shares |
| Eric Pauwels(Chief Business Officer) | Adoption (December 13, 2024) | Rule 10b5-1 trading arrangement | Sale | Until May 30, 2025, or such earlier date upon which all transactions are completed. | Up to 110,799 shares |
| Neil Almstead (Chief Technical Operations Officer) | Adoption (December 10, 2024) | Rule 10b5-1 trading arrangement | Sale | Until March 31, 2026, or such earlier date upon which all transactions are completed | Up to 396,436 shares |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.